Individualized chemotherapy and immunotherapy for rectal cancer: the next step forward
- PMID: 36797850
- DOI: 10.1111/ans.18235
Individualized chemotherapy and immunotherapy for rectal cancer: the next step forward
References
-
- Prabhakaran S, Yang TWW, Johnson N et al. Latest evidence on the management of early-stage and locally advanced rectal cancer: a narrative review. ANZ J. Surg. 2022; 92: 365-72.
-
- Bahadoer RR, Dijkstra EA, van Etten B et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22: 29-42.
-
- Conroy T, Bosset JF, Etienne PL et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22: 702-15.
-
- Kong JC, Soucisse M, Michael M et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes. Ann. Surg. Oncol. 2021; 28: 7476-86.
-
- Santiago I, Figueiredo N, Parés O, Matos C. MRI of rectal cancer-relevant anatomy and staging key points. Insights Imaging 2020; 11: 100.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources